Bernsen H J, Rijken P F, Peters H, Bakker H, van der Kogel A J
Institute of Radiotherapy, University of Nijmegen, The Netherlands.
J Neurooncol. 1998 May;38(1):51-7. doi: 10.1023/a:1005957201431.
The effect of the anti-angiogenic agent TNP-470 on tumor growth, vascular area, vascular density and tumor perfusion of two different subcutaneously implanted human glioma xenografts (E98 and E106) in nude mice was evaluated. Vascular parameters were investigated with an image analysis system. For both tumor lines a small but significant tumor growth suppression was observed. However, no differences in vascular parameters between TNP-470 treated tumors and controls could be found after 6 weeks of treatment. It is concluded that although TNP-470 is a promising anti-angiogenic agent in many tumor types, at least 2 glioma lines seem to be partly resistant to its anti-angiogenic effects. Further evaluation of the effects of combination of TNP-470 and cytostatic agents or radiotherapy in human glioma xenografts are required to determine the place of anti-angiogenic therapy in general and treatment with the anti-angiogenic agent TNP-470 more specifically in the treatment of human gliomas.
评估了抗血管生成剂TNP - 470对裸鼠体内两种不同皮下植入的人胶质瘤异种移植瘤（E98和E106）的肿瘤生长、血管面积、血管密度和肿瘤灌注的影响。使用图像分析系统研究血管参数。对于两种肿瘤细胞系，均观察到轻微但显著的肿瘤生长抑制。然而，治疗6周后，未发现TNP - 470治疗组肿瘤与对照组之间的血管参数存在差异。得出的结论是，尽管TNP - 470在许多肿瘤类型中是一种有前景的抗血管生成剂，但至少有2种胶质瘤细胞系似乎对其抗血管生成作用部分耐药。需要进一步评估TNP - 470与细胞抑制剂或放疗联合应用于人胶质瘤异种移植瘤的效果，以确定抗血管生成治疗总体上的地位，以及更具体地确定抗血管生成剂TNP - 470在人胶质瘤治疗中的地位。
